Nektar's Rezpegaldesleukin Shows Early Biomarker Response in Atopic…

Event summary

Nektar Therapeutics presented new biomarker data from a REZOLVE-AD sub-study at EADV Congress 2026, showing early molecular responses to rezpegaldesleukin in atopic dermatitis patients.
Significant biomarker changes associated with clinical improvement were observed as early as Week 2 of treatment.
The Phase 2b REZOLVE-AD study included 100 patients, with 59 receiving rezpegaldesleukin and 41 receiving placebo.
Rezpegaldesleukin demonstrated rapid Treg-associated molecular changes and normalization of multiple immune pathways.
The data support rezpegaldesleukin's potential as a Treg-directed approach for heterogeneous inflammatory diseases.

The big picture

Nektar Therapeutics' rezpegaldesleukin aims to address a significant unmet need in atopic dermatitis, where over 50% of adults report inadequately controlled disease despite current treatments. The biomarker data presented at EADV Congress 2026 highlight the potential of rezpegaldesleukin's Treg-stimulating mechanism to normalize dysregulated immune pathways, positioning it as a novel approach in the competitive landscape of autoimmune and inflammatory disease therapies. The strategic focus on early molecular responses and their correlation with clinical outcomes underscores Nektar's efforts to differentiate its lead candidate in a market dominated by biologics targeting type 2 inflammation.

What we're watching

Clinical Validation: Whether the early molecular responses observed in the REZOLVE-AD sub-study will translate into sustained clinical benefits in future Phase 3 trials.
Regulatory Pathway: The pace at which Nektar Therapeutics can advance rezpegaldesleukin through Phase 3 trials and secure regulatory approvals for atopic dermatitis and other indications.
Market Differentiation: How rezpegaldesleukin's differentiated mechanism of action will position it against existing biologics in the atopic dermatitis market.